Insmed's lung infection drug succeeds in late-stage trial
July 1 (Reuters) - Insmed Inc said a late-stage trial of its experimental lung infection drug showed the therapy was as effective as another approved treatment.
The drug, Arikace, was being tested as a treatment for a bacterial infection in cystic fibrosis patients. The trial met its main goal of showing Arikace was not inferior to Tovi, Novartis's drug for the same infection.
- Atheists face death in 13 countries, global discrimination: study
- Signer says suffered schizophrenic episode at Mandela memorial |
- Missouri executes man for killing good Samaritan motorist in 1994
- Thai military chief rebuffs meeting request in blow to protesters |
- Apple scores legal victory over Samsung in South Korea